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Introduction: Esophageal cancer remains a highly lethal malignancy, with therapeu-
tic options of limited efficacy in the majority of patients. Understanding the
molecular events involved in the pathogenesis of esophageal cancer offers insight
into potential targets for treatment. Beta catenin and Wnt signaling abnormalities are
involved in the development of both adenocarcinoma and squamous carcinoma of
the esophagus. We hypothesized that down-regulation of beta catenin would inhibit
the growth of human esophageal cancer.
Methods: A human esophageal squamous cell carcinoma cell line (TE10) was
treated with phosphorothioate antisense oligonucleotides to beta catenin. The cells
were subsequently assayed for beta catenin mRNA and protein by real-time poly-
merase chain reaction and Western blot. Beta catenin transcriptional activity was
determined by TOPFlash assay. Cell viability and growth was assessed by methyl-
thiazol-diphenyl-tetrazolium assay and trypan blue exclusion. A colorimetric assay
was employed to assess caspase 3 activity, and flow cytometry was done to
determine percentage of cells in a given phase of the cell cycle.
Results: Following antisense treatment, beta catenin mRNA and protein concentra-
tion were decreased. There was corresponding decrease in beta catenin–transcrip-
tion factor–dependent transcription. Treatment with beta catenin antisense resulted
in significantly decreased cell viability and proliferation. The mechanism appears to
be increased induction of apoptosis.
Conclusions: These data suggest a potential role for the targeting of beta catenin in
the treatment of esophageal cancer.
Esophageal cancer ranks as the sixth most frequent cause of cancerdeath in the world and the seventh most common cause of cancerdeath in the United States.1 Despite significant advances in screen-ing, surgical care, and chemoradiotherapy techniques, the overall5-year survival for patients with esophageal cancer is 13%.2 Most ofthese treatment failures are due to metastatic disease resistant to
systemic therapy. Although novel chemotherapeutic regimens are currently being
developed, many patients are unable to tolerate the toxicities associated with these
agents. Identification of the genetic defects responsible for the development of
esophageal malignancies and the development of therapies that reverse these defects
represent potentially useful adjuncts to the therapy of this lethal disease.
Beta catenin and other proteins in the Wnt signaling pathway play a role in the
pathogenesis of many human cancers, including esophageal cancer. Beta catenin is
involved in cell-cell adhesion by its interaction with the cytoskeleton and cadherin
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junctions.3 Beta catenin also serves as a transcription factor
(TCF).4 Transcriptionally active beta catenin, derived from
membrane bound beta catenin and a free cytoplasmic pool
of beta catenin,5 is found in the nucleus and has been
implicated in the transcription of oncogenes such as c-jun,6
c-myc,7 and cyclin D1.8 The adenomatous polyposis coli
(APC) gene product forms a complex with other proteins,
and targets beta catenin for degradation and prevents beta
catenin–dependent transcription.9 Binding of the Wnt li-
gand to its transmembrane Frizzled (Fz) receptors protects
beta catenin from APC-mediated degradation and increases
beta catenin–dependent transcription.10 Mutations in Wnt
pathway elements have been described in both squamous
cell carcinoma and adenocarcinoma of the esophagus. A
number of histopathologic studies have shown abnormal
localization of beta catenin in the nucleus in adenocarci-
noma cells associated with Barrett’s metaplasia.11 Muta-
tions in beta catenin itself12,13 or in APC14 have been found
infrequently in patients with esophageal adenocarcinoma.
However, loss of heterozygosity in the APC gene was noted
in 60% of adenocarcinoma arising from Barrett’s metapla-
sia.15 In addition, there is an increased incidence of abnor-
mal beta catenin expression in the sequence of low-grade
dysplasia to adenocarcinoma of the esophagus.16 Gene pro-
file experiments have demonstrated beta catenin to be one of
very few genes to be differentially overexpressed in speci-
mens of adenocarcinoma of the esophagus.17 Similarly,
studies of squamous cell esophageal carcinomas have dem-
onstrated increased cytoplasmic beta catenin,18 with no mu-
tations in beta catenin itself.19 This increased cytoplasmic
beta catenin may be due to the presence of a mutation in the
Wnt receptor, the Fz gene product. In support of this hy-
pothesis, Tanaka and colleagues20 have demonstrated an
increased incidence (86%) of activating mutations of the Fz
gene product in the progression of well differentiated to
poorly differentiated squamous cell carcinoma.
Targeted suppression of beta catenin using phosphoro-
thioate antisense oligonucleotides has been demonstrated to
inhibit the growth of colon cancer cells in vitro and in vivo
by means of induction of apoptosis and cell cycle arrest
(data submitted for publication).21 Because abnormal beta
catenin expression is associated with neoplastic progression
in esophageal cancer, we hypothesized that down-regulation
of beta catenin would result in the inhibition of esophageal
cancer cell growth. Using phosphorothioate antisense oli-
gonucleotide directed against beta catenin mRNA, we have
examined the role of beta catenin signaling in the neoplastic
growth of esophageal cancer cells in vitro.
Materials and Methods
Cell Lines
Human esophageal cancer cell lines TE7, TE8, TE9, TE10, and
TE11 were obtained from Dr Tetsuro Nishihira and Dr Toshio
Kudo of Tohoku University, Sendai, Japan. These cell lines were
cultured under usual conditions of 37°C under 5% carbon dioxide,
in RPMI supplemented with 10% fetal bovine serum, 100 units/mL
penicillin, and 100 g/mL streptomycin.
Oligonucleotides and Cell Treatment Protocol
Phosphorothioate oligonucleotides (ODN) directed against beta
catenin were synthesized (Trilink Biotechnologies Inc, San Diego,
Calif) as described previously.21 Beta catenin antisense sequence
was 5'-TAAGAGCTTAACCACAACTG-3'. The scrambled con-
trol was 5'-CAGTAATCGAATAGCTACCA-3'. All experiments
were done in triplicate, with both scrambled control and lipid
carrier alone (Effectene; Qiagen, Valencia, Calif) treatment con-
trols.
Antisense treatment was performed by plating 106 cells into
100-mm plates and allowing the cells to adhere overnight. Cells
were washed in Optimem (Gibco, Grand Island, NY), and medium
was replaced with one containing ODN for a 4-hour period.
Transfection of ODN was mediated using the lipid carrier Effect-
ene. On the basis of the manufacturer’s recommendation, 15 L of
Effectene was used to suspend 6 g of ODN, to a maximal
concentration of 3.75 L Effectene/mL of RPMI medium. Cells
were exposed to Effectene-ODN for 4 hours, then supplemented
with fresh medium. This treatment was repeated 24 hours after
initial treatment.
Antibodies and Western Blots
Total cellular protein extracts were obtained by lysis of tumor cells
in lysis buffer (50 mmol/L Tris-HCl pH 7.4, 5 mmol/L ethylene
glycol tetraacetic acid (EGTA), 1% Triton X-100, 150 mmol/L
NaCl, 2 mmol/L phenylmethylsulfonyl fluoride, 1% aprotinin, and
5 g/mL leupeptin) 48 hours after antisense treatment. Nuclear-
enriched cell extract was obtained by lysis of cells in low-salt
buffer (10 mmol/L HEPES, 10 mmol/L KCl, 0.1 mmol/L ethyl-
enediaminetetraacetic acid [EDTA], 0.1 mmol/L EGTA, 0.5
mmol/L phenylmethylsulfonyl fluoride, 1% aprotinin, 5 g/mL
leupeptin, and 10% NP-40; pH 7.9), low speed (0.4g) centrifuga-
tion to pellet the nuclear fraction, and subsequent lysis in a
high-salt buffer (20 mmol/L HEPES, 0.4 mol/L NaCl, 1 mmol/L
EDTA, 1 mmol/L EGTA, with 1% aprotinin and 5 g/mL leupep-
tin). Protein concentration was obtained by Coomasie assay
(Pierce; Rockford, Ill). Equal amounts of protein were subjected to
sodium dodecyl–polyacrylamide gel electrophoresis and electro-
botted onto PVDV membrane. Protein-specific antibodies directed
against beta catenin, tubulin, and cyclin D1 were obtained from
Santa Cruz Biotechnology (Santa Cruz, Calif) and Oncogene Re-
search (Cambridge, Mass) and used according to manufacturer’s
recommendations. Alpha- and beta-tubulin–specific antibodies
were used as control for equal protein loading. Appropriate sec-
ondary antibodies conjugated to horseradish peroxidase were used,
and binding affinity assessed by electrochemoluminescence (Am-
ersham Biosciences, Buckinghamshire, United Kingdom) expo-
sure of radiographic film.
Analyzing Beta Catenin mRNA Expression Using
Real-Time Polymerase Chain Reaction Analysis
Beta catenin mRNA levels were determined using a real-time
polymerase chain reaction (RT-PCR) technique. In brief, total
cellular RNA was extracted from TE10 cells with TRIzol reagent
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(Life Technologies, Carlsbad, Calif) 48 hours after treatment with
antisense ODN directed against beta catenin. Using the Taqman
assay system (Applied Biosystems, Foster City, Calif) cDNA was
generated and subsequently amplified. Standardized primers spe-
cific for beta catenin and glyceraldehyde-3-phosphate dehydroge-
nase (Applied Biosystems) were used in this assay. To generate the
standard curves, the crossing points of the standards were plotted
against the logarithm of their concentrations (range 1010 to 1012
copies/mL). The thermal cycling conditions were an initial dena-
turation step at 95°C for 10 minutes, 40 cycles at 95°C for 15
seconds, and 60°C for 1 minute. An ABI Prism 5700 sequence
detection system (Applied Biosystems) was used.
Beta Catenin/TCF Reporter Assay
Cells were treated with antisense in the described manner. Four
hours after the second and final treatment, the culture medium was
replaced and cells were transfected with TOPFlash (Upstate Bio-
technology, Waltham, Mass) reporter vector. TOPFlash contains
consensus sequence of Tcf/Lef enhancer, upstream of luciferase
enzyme coding region. To serve as internal control for transfec-
tion, cells were cotransfected with a non-Tcf/Lef–dependent beta-
galactosidase coding vector. The ratio of TOPFlash to beta-galac-
tosidase activity represented beta catenin/Tcf activity.
One million antisense-treated cells were cotransfected with 0.5
g of TOPFlash vector and 2 g of beta galactosidase vector,
using Effectene transfection reagent according to manufacturer’s
recommendations. Twenty-four hours after transfection, cells were
lysed with cell culture lysis reagent (Promega; Madison, Wis), and
beta galactosidase activity was measured with a beta galactosidase
enzyme assay system (Promega). The same lysate was assayed for
luciferase activity with a commercially available luciferase assay
(Promega). Luciferase activity was normalized to beta galactosi-
dase activity.
FACScan/Cell Cycle Analysis
Cells were detached from the plate with trypsin and fixed in cold
70% ethanol. Cells were then digested with solution containing
RNAse A (100 units/mL, Roche) and stained with 50 g/mL
propidium iodide. DNA content was assessed with FACSscan flow
cytometer, and analysis was done with FlowJo v 4.2 analysis
software (Tree Star Inc, San Carlos, Calif).
Cell Growth and Methyl-Thiazol-Diphenyl-
Tetrazolium Assay
Viable cell number was determined counting trypan blue excluded
cells. Methyl-thiazol-diphenyl-tetrazolium (MTT) assay was per-
formed by plating antisense-treated cells into 96 well plates. MTT
was added to each well for final concentration of 500 g/mL. After
4 hours of incubation at 37°C, the fomazan product was solubi-
lized in 10% sodium dodecyl/0.01N HCl. The absorbance of 595
nm was recorded, using 650-nm reference length (model 3550
Microplate Reader, Bio-Rad, Hercules, Calif). Results reported are
the mean of 5 treatments.
Apoptosis Determination
Forty-eight hours after treatment, cells were detached from their
plates with trypsin and washed in phosphate-buffered saline solu-
tion. Activation of caspase 3 was determined using ApoAlert
Caspase-3 Colorimetric Assay Kit (Clontech, Palo Alto, Calif),
according to manufacturer’s protocol. Annexin V staining was
done using Annexin V–FITC Apoptosis Kit (BioSource Interna-
tional Inc, Camarillo, Calif), according to manufacturer’s protocol.
Statistical Analysis
For Western blots, a representative blot from repeated experiments
is shown. For other experiments, results represent the means of a
minimum of triplicate samples and are presented as mean  SE.
Analysis of variance with Newman-Keuls multiple comparison
test (P  .05) defined significance.
Results
Esophageal Cancer Cell Lines Contain Beta Catenin
Multiple esophageal cancer cell lines were examined for
beta catenin protein expression. Although Western blotting
revealed beta catenin in all esophageal cancer cell lines, the
greatest expression was noted in the highly differentiated
squamous cell carcinoma cell lines TE10 and TE11 cells
lines (Figure 1, A). We chose to use the TE10 cell line in
subsequent experiments.
Antisense Treatment Decreases Beta Catenin mRNA
and Protein Expression
Treatment of esophageal cancer cells with antisense ODN
directed against beta catenin resulted in decreased levels of
beta catenin mRNA, relative to scramble treatment (51%
reduction; P .01; Figure 1, B), and decreased nuclear beta
catenin protein levels 48 hours after initial treatment (Figure
1, C). Although beta catenin protein levels in the total cell
lysate was minimally decreased at this 48 hour time point
(data not shown), there was a marked reduction in beta
catenin protein in the nuclear fraction. This difference likely
reflects the slow turnover of membrane-bound beta catenin.
Antisense Treatment Decreases Beta
Catenin–Dependent Transcription
Because total cellular lysates contain beta catenin bound to
the cell membrane and the nuclear contents containing
transcriptionally active beta catenin, evaluation of the nu-
clear fraction alone is a better indication of changes in
transcriptionally active beta catenin. In an effort to deter-
mine whether the decreased nuclear beta catenin resulted in
decreased beta catenin transcriptional function, we per-
formed a beta catenin/Tcf–sensitive reporter assay.
Following ODN treatment, a luciferase reporter gene
under the control of a beta catenin/Tcf–sensitive element
was transfected into TE10 cells. We noted a 36% decrease
in luciferase reporter activity in cells treated with beta
catenin ODN relative to scrambled control (Figure 1, D).
Esophageal cancer cell viability and growth is inhibited by
beta catenin antisense treatment. In a representative exper-
iment, treatment with phosphorothioate antisense oligonu-
cleotide resulted in significant inhibition of cell growth by
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MTT assay 3 days after single treatment, compared with
scrambled control (59% reduction, P  .01; Figure 2, A).
Treatment of cells with oligonucleotide on consecutive days
had similar effect on directly measured cell growth. There
was an 80% decrease in cell number, with beta catenin
antisense treatment relative to scrambled control (P  .01;
Figure 2, B).
Caspase 3 Activity Is Increased by Beta Catenin
Antisense Treatment
We sought to determine the mechanism responsible for the
beta catenin antisense–mediated inhibition of TE10 cell
growth. A decrease in the number of viable cells may be due
to induction of apoptosis. Caspase 3, a protease, is the
terminal effector of the apoptotic pathway. Direct colori-
metric assay of caspase 3 activity showed increased activity
with antisense treatment relative to scrambled control (59%;
P  .01; Figure 3, A). This increase in directly measured
caspase activity was corroborated with annexin staining for
apoptotic cells (data not shown).
Inhibition of TE10 Cell Growth Is Not Associated with
Cell Cycle Arrest
Cell cycle arrest may also contribute to growth inhibition.
Cyclin D1 expression is necessary for the progression of the
cell through the G0/G1 phase of the cell cycle, and its
expression is transcriptionally regulated by beta catenin/Tcf
in some cells. We hypothesized that down-regulation by
beta catenin would be associated with a decrease in cyclin
D1 and increase in the number of cells in the G0/G1 phase
of the cell cycle. However, in TE10 cells, down-regulation
of beta catenin was not associated with a decrease in cyclin
D1 expression, and cell cycle analysis revealed no change in
the fraction of esophageal tumor cells in the G0/G1 phase of
the cell cycle (Figure 3, B and C).
Discussion
Beta catenin and elements of the Wnt signaling elements
have been found to play an important role in the pathogen-
esis of human cancer. Phosphorothioate antisense oligonu-
cleotides provide a potent technology to specifically inhibit
a given mRNA target. We have previously demonstrated
antisense-mediated down-regulation of beta catenin expres-
sion in multiple human colon cancer cell lines containing
increased beta catenin activity, with resulting inhibition of
cell growth in vitro and in vivo.22 Beta catenin mRNA and
protein levels in the colon cancer xenografts were signifi-
cantly depressed after ODN treatment. In this colon cancer
model, inhibition of cell growth was mediated both by cell
Figure 1. A, Western blot revealed variable beta catenin protein expression in TE cell lines assayed. The greatest
concentration was noted in TE10 and TE11 cell lines. Protein was loaded (10 g per lane). Equal concentration of
tubulin was present. B, RT-PCR showed decrease in beta catenin mRNA copy number relative to controls (P < .01).
C, Western blot of nuclear lysate derived from antisense treated cells was devoid of beta catenin. D, TOPFlash, a
beta catenin-depended luciferase assay, demonstrated decreased luciferase activity, with beta catenin antisense
treatment.
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cycle arrest and induction of apoptosis (data submitted for
publication).
In the current study, inhibition of beta catenin by specific
phosphorothioate antisense oligonucleotides resulted in a
significant decrease in esophageal cancer cell growth. This
inhibition was characterized by induction of apoptosis but
not cell cycle arrest. In contrast to beta catenin signaling in
colon cancer cells, down-regulation of beta catenin in
esophageal cancer cells did not result in a decrease in cyclin
D1 expression. Collectively these findings suggest that reg-
ulation of cyclin D1–mediated cell cycle progression in
TE10 cells occurs independently of beta catenin/Tcf–medi-
ated transcription. This finding may be clinically significant
because increased cyclin D1 expression has been demon-
strated to be a poor prognostic sign in patients with esoph-
ageal cancer.23 As an alternative, the EGFR pathway has
Figure 2. MTT assay performed 3 days after treatment demonstrated significant decrease in cell viability in those
cells treated with beta catenin phosphorothioate antisense oligonucleotide (P < .01).
Figure 3. Direct assay of cell viability by trypan blue staining similarly demonstrated significant decrease in cell
growth in those cells treated with beta catenin phosphorothioate antisense oligonucleotide (P < .01).
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been demonstrated to be activated in esophageal malignan-
cies, as well as our esophageal cancer model, and is known
to regulate cyclin D1 expression.24
Despite this apparent lack of inhibition of cell cycle
progression, we did document decreased cancer cell growth,
possibly by means of apoptotic induction. The specific
mechanism of induction of apoptosis remains to be eluci-
dated. Apoptotic signaling pathways arising from the mito-
chondria as well as receptors, and structural components of
the cell membrane have been identified.25 Activation of Wnt
signaling has been shown to inhibit induction of apopto-
sis.26 Because many chemotherapeutic agents function by
inducing apoptosis, activation of the Wnt signaling pathway
through beta catenin may lead to chemotherapeutic resis-
tance.26
The use of oligonucleotides to inhibit a specific protein’s
expression and cause a desired inhibition of growth has
been demonstrated in a number of tumor models. When
appropriately designed, phosphorothioate oligonucleotides
have high degree of specificity to their target and have
minimal nonspecific effects, such as activation of inflam-
matory response in vivo.27In preliminary work, we have
demonstrated inhibition of polyp formation in the intestines
of APC mutant mice, using long-term antisense treatment
targeting murine beta catenin.28 The mice appeared to tol-
erate systemic down-regulation of beta catenin, perhaps
because of biological redundancy, and the ability of other
proteins to substitute for the functions of beta catenin.29
Antisense compounds have also been shown to potentiate
the effects of chemotherapeutic agents.
This initial study has demonstrated the inhibition of the
growth of squamous cell carcinoma of the esophagus by
down-regulation of beta catenin. There exists a potential
benefit for combining beta catenin antisense treatment with
traditional chemotherapeutic agents. Preliminary work in a
colon cancer xenograft model using this same antisense
ODN has shown significant inhibition of tumor cell growth
with the combination of beta catenin antisense oligonucle-
otides and conventional chemotherapeutic agents.30 Anti-
sense targeting of beta catenin may have a role in the
development of potent treatments for cancer of the esoph-
agus.
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Discussion
Dr W. Roy Smythe (Houston, Tex). I have 2 questions about your
assays that you did after your antisense treatment. First, did you
look at the other catenins for the cadherins to make sure that with
your antisense you weren’t actually down-regulating multiple
components of that pathway by Western blot or other means?
And second, do you have an idea of sort of the overall amount
of apoptosis as measured by either subG1 FACS or annexin V or
something like that? I don’t really have a good idea about just how
much apoptosis you’re seeing with an increase in caspase 3 activ-
ity.
Dr Veeramachaneni (St Louis, Mo). In answer to your first
question, we did not specifically look at cadherins in this popula-
tion of cells.
As for means of apoptosis, you’re absolutely right. One mea-
sure of apoptosis, such as caspase 3, is not enough to prove our
point. We corroborated our caspase 3 assay using annexin V
staining and we were able to show an increase in apoptotic cells.
Dr Smythe. What would you say the total percentage of
apoptosis is by annexin V?
Dr Veeramachaneni. About 10% after a single treatment at 24
hours after treatment.
Dr Smythe. So an elevation that’s still a pretty low amount?
Dr Veeramachaneni. Correct.
Dr David A. Jones (Charlottesville, Va). What was your
timeline for apoptosis with your antisense treatment? How long
did it last? How long did it take before you saw some apoptosis?
And also, did you do any studies kind of looking at the end
gene products of the beta catenin signaling pathway such as cyclin
D1 or some of your metalloproteinases by either at a protein or an
mRNA level once you treated with the antisense?
Dr Veeramachaneni. Looking at other downstream targets of
the Wnt signaling pathway was rather interesting in these cells.
Most of our laboratory’s experience is in the colon cancer cell line.
In the colon cancer cell lines, we note not only an induction of
apoptosis but also cell cycle arrest with targeting of beta catenin.
In those cell lines we were able to show a decrease in cyclin D1
and associated FACS analysis increase in G1 fraction.
These (TE10) cell lines, however, don’t behave that way. When
we specifically looked at cell cycle inhibition as a potential role in
how beta catenin antisense is working, we were not able to
demonstrate that mechanism. We saw no change in cyclin D1
expression both by RT-PCR as well as protein expression.
We also looked at a number of other targets of the beta catenin
signaling pathway we were able to demonstrate MDR inhibition.
MDR is another name for P-glycoprotein and has been implicated
in chemoresistance.
As far as the first part of your question, looking at the maximal
time for apoptosis, we translated what we knew from our colon
cancer cell model to this cell model. In the colon cancer cell
model, we see a decrease in beta catenin as early as 30 minutes
after antisense treatment, the effect lasts for about 3 days, and
maximal apoptotic activity is seen at about 48 to 72 hours. And we
chose the same time points in this study.
Dr Raphael Bueno (Boston, Mass). Do you know what hap-
pens when you put beta catenin into normal cells? I mean, do all
cells get apoptotic and die, or do specific cancer cells only get
apoptotic and die?
Dr Veeramachaneni. I’m sorry, did you ask if by inhibiting
beta catenin whether all cells die?
Dr Bueno. I mean, did you just do the experiments in colon
cancer and then in esophageal cancer cell lines, or did you do it in
some cell lines that do not die? I’m just trying to figure out if this
is a general necessary gene that if you inhibit it anything dies, or
is it a specific mechanism of esophageal cancer and if you inhibit
it, the cancer cells die?
Dr Veeramachaneni. We looked at a number of colon cancer
cell lines, some of which have high levels of beta catenin expres-
sion as well as function. In those cell lines that do not have an avid
Wnt signaling cascade, beta catenin antisense has no effect.
So the short answer to your question is, this is a specific
process. In our experience, if the cell line does not have an active
Wnt signaling pathway driving the carcinogenic pathway, this
probably has no effect.
Dr Dao M. Nguyen (Bethesda, Md). Have you done any
immunostaining to find out the cell localizations of beta catenin,
which is very highly expressed in this cell line?
Dr Veeramachaneni. In these cell lines we have not done
those studies.
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